T-Cypher Bio
Hemza Ghadbane is currently serving as the Senior Director and Head of Gene Editing at T-Cypher Bio since January 2022. Prior to this role, Hemza held positions as Principal Scientist and Senior Scientist at Immunocore from September 2015 to December 2021. Hemza began their career as a Post-doctoral scientist at Oxford University from October 2009 to August 2015. Hemza holds a Ph.D. in Biosciences from the University of Birmingham, which was completed between 2005 and 2009, and a BSc in Pharmaceutical Sciences from The University of Manchester, achieved between 2002 and 2005.
This person is not in any teams
T-Cypher Bio
T-Cypher Bio is an early-stage biotechnology company. T-Cypher Bio we believe that TCR-based therapeutics have the potential to transform the treatment of solid tumors, as well as autoimmune, inflammatory, and infectious diseases. Yet challenges in the identification of therapeutically relevant targets and TCRs have limited the application of suchtherapies.T-Cypher’s integrated platform, D-Cypher, overcomes these challenges.